Experimental cell therapy takes on tough lung cancer
Disease control
Terminated
This early-phase study tested a personalized cell therapy (C-TIL051) for people with advanced non-small cell lung cancer that no longer responded to anti-PD1 drugs. Participants provided a tumor sample to create the therapy, then received chemotherapy, the cell infusion, and addi…
Phase: PHASE1 • Sponsor: AbelZeta Inc. • Aim: Disease control
Last updated Apr 23, 2026 12:45 UTC